Most Clicked StoriesMore >


$15.7B biotech fund proposed by mayor of London

BIO SmartBrief | Jun 26, 2015

A biotech fund worth $15.7 billion was proposed by London Mayor Boris Johnson to finance drug development projects and encourage the growth of biotech companies in the city. "London is one of the most powerful scientific discovery engines in the world. We hope to harness our role as a global financial center that will bring more lifesaving drugs to market and deliver a huge boost to the economy," Johnson said. Bloomberg (06/25) Genetic Engineering & Biotechnology News (06/25)


Report: Biosimilar market to expand rapidly

BIO SmartBrief | Jul 02, 2015

Baxter announces Baxalta spinoff

BIO SmartBrief | Jul 02, 2015

Celgene, Juno sign $1B collaboration deal

BIO SmartBrief | Jun 30, 2015

Bristol-Myers Squibb ceases antiviral discovery program

BIO SmartBrief | Jun 29, 2015

Judge rules against biotech crop ban in Maui County

BIO SmartBrief | Jul 01, 2015

Rheumatoid arthritis biosimilar drugs termed equivalent

BIO SmartBrief | Jun 26, 2015

Novartis acquires biotech firm Spinifex

BIO SmartBrief | Jun 30, 2015

Drugs from Immunovaccine, Incyte to be combined in cancer trial

BIO SmartBrief | Jun 29, 2015

Juno's lymphoma drug application accepted by FDA

BIO SmartBrief | Jun 30, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


Secure document sharing services optimized for life science organizations

BIO SmartBrief | Jul 02, 2015

Savings on environmental waste disposal services

BIO SmartBrief | Jul 02, 2015

Industrial biotechnology with a French twist!

BIO SmartBrief | Jul 01, 2015

Faster & better connections with quality R&D vendors

BIO SmartBrief | Jul 01, 2015

Find the experienced biotech talent that your company needs

BIO SmartBrief | Jun 30, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more